Calyxo develops the CVAC System, an all-in-one aspiration-based platform that uses irrigation and vacuum aspiration to continuously clear kidney stone fragments during and after laser lithotripsy. The CVAC System was FDA-cleared in 2024 and aims to enable more complete stone clearance, which the company says drives improved clinical outcomes. Clinical, preclinical, and health economic evidence cited by Calyxo report low residual stone volume, improved procedural efficiency, and reductions in downstream healthcare utilization and cost. The company announced that over 40,000 patients have been treated with the CVAC System, signaling growing physician adoption. Calyxo plans to use newly raised capital to expand commercial infrastructure, generate further clinical and health-economic evidence through ongoing and future studies, and continue product innovation. The company describes itself as focused on paradigm-shifting solutions to improve kidney stone care.

Total raised

$123M

Funding rounds

3

Latest round

Series F

Latest activity

Apr 2026